氯化柯喃炔水合物 | 38989-38-7

• 物质功能分类: 天然产物 - 生物碱
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 氯化柯喃炔水合物
• 中文别名: 柯楠因
• 英文名称: coralyne chloride
• 英文别名: coralyne；2,3,10,11-tetramethoxy-8-methyldibenzo[a,g]quinolizinium chloride；Coralyn-chlorid；2,3,10,11-tetramethoxy-8-methylisoquinolino[2,1-b]isoquinolin-7-ium;chloride
• CAS: 38989-38-7
• 化学式: C₂₂H₂₂NO₄*Cl
• 分子量: 399.874
• InChiKey: PDYBUYVOPAJLKP-UHFFFAOYSA-M

物化性质

• 熔点：
  215°C
• 溶解度：
  DMSO:5.0(最大浓度 mg/mL);12.5(最大浓度 mM)水:5.0(最大浓度 mg/mL);12.5(最大浓度 mM)
• 碰撞截面：
  186.7 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]
• 稳定性/保质期：
  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.08
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  41
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S45
• 危险类别码：
  R25
• 海关编码：
  2933990090
• 储存条件：
  存放于2-8℃阴凉干燥处

SDS

Name:	Coralyne Chloride Hydrate 98+% Material Safety Data Sheet
Synonym:	8-Methyl-2,3,10,11-Tetramethoxydibenzo(A,G)Quinolizinium Chloride
CAS:	38989-38-7

Section 1 - Chemical Product MSDS Name:Coralyne Chloride Hydrate 98+% Material Safety Data Sheet
Synonym:8-Methyl-2,3,10,11-Tetramethoxydibenzo(A,G)Quinolizinium Chloride

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
38989-38-7	Coralyne Chloride, Hydrate	98+	254-239-2

Hazard Symbols: T
Risk Phrases: 25

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Toxic if swallowed.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 38989-38-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: orange
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 215 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: > 215 deg C
Solubility in water: insoluble
Specific Gravity/Density:
Molecular Formula: C22H22ClNO4.xH2O
Molecular Weight: 399.86

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 38989-38-7: HQ1812000 LD50/LC50:
Not available.
Carcinogenicity:
Coralyne Chloride, Hydrate - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: T
Risk Phrases:
R 25 Toxic if swallowed.
Safety Phrases:
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 38989-38-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 38989-38-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 38989-38-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

氯化珊瑚碱是一种原小檗碱生物碱，具有很强的抗癌活性。珊瑚酰氯作为一种有效的拓扑异构酶I抑制剂，可以诱导Top I介导的DNA切割。珊瑚烯氯化物还可用于制备珊瑚烯衍生物作为DNA结合荧光探针。

反应信息

• 作为反应物：
  描述：

  氯化柯喃炔水合物 反应 3.0h， 生成
  参考文献：
  名称：

  生物碱反应性：选择性脱甲基反应的DFT分析

  摘要：

  本文描述了通过DFT计算的各种季生物碱所有可能的脱甲基反应。我们旨在建立一个合理的模型，该模型可以解释实验观察到的高选择性并预测新生物碱衍生物的出现。为此，我们对初始试剂和产品进行了详细的分析。另外，作为概念的证明，已经进行了实验上未知的珊瑚烯脱甲基反应，从而验证了本文提出的理论模型的可靠性。

  DOI：

  10.1021/acs.joc.8b02364

文献信息

• Compounds and methods for modulating Rho GTPases
  申请人：Exonhit Therapeutics SA

  公开号：EP2014651A1

  公开（公告）日：2009-01-14

  The present invention relates to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac GTPases (Rac1, Raclb, Rac2 and/or Rac3).

  本发明涉及影响Rho家族GTP酶的GTP结合活性的方法和组合物，优选是Rac GTP酶（Rac1、Raclb、Rac2和/或Rac3）。
• Studies on α-, β-, and γ-cyclodextrin inclusion complexes of isoquinoline alkaloids berberine, palmatine and coralyne
  作者：Soumitra Hazra、Maidul Hossain、Gopinatha Suresh Kumar

  DOI：10.1007/s10847-013-0301-6

  日期：2014.4

  palmatine. The thermodynamic parameters of the complexation were determined by calorimetry. The stoichiometry of complex formation and the variation of the apparent binding constant from spectroscopic studies were confirmed by calorimetry. The formation of the inclusion complexes was entropy driven in almost all the systems. Coralyne formed the strongest complex with all the CDs, followed by berberine and

  通过吸收、荧光、圆二色性、核磁共振光谱和微量热分析技术研究了三种异喹啉生物碱小檗碱、巴马汀和珊瑚碱与 α-、β-和γ-CDs 的络合。它们的结合常数 (KBH) 值由 Benesi-Hildebrand 方程确定。所有生物碱与环糊精 (CD) 形成 1:1 化学计量的复合物。β-CD 的结合亲和力最大，其次是 γ-，和 α-CD 对珊瑚碱，其次是小檗碱，然后是巴马汀。络合的热力学参数通过量热法测定。复合物形成的化学计量和来自光谱研究的表观结合常数的变化通过量热法证实。在几乎所有系统中，包合物的形成都是由熵驱动的。Coralyne 与所有 CD 形成最强的复合物，其次是小檗碱和巴马汀。通过核磁共振研究了 Coralyne-β-CD 复合物，表明有不止一种相互作用模式。
• COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES
  申请人：Leblond Bertrand

  公开号：US20100120810A1

  公开（公告）日：2010-05-13

  The present invention relates to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac GTPases (Rac1, Rac1b, Rac2 and/or Rac3).

  本发明涉及影响Rho家族GTP酶成员的GTP结合活性的方法和组合物，优选是Rac GTP酶（Rac1，Rac1b，Rac2和/或Rac3）。
• Treatment of aberrant fibroblast proliferation
  申请人：Georg August Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin

  公开号：US11331333B2

  公开（公告）日：2022-05-17

  Provided is a method of preventing, treating or delaying progression of a disease involving aberrant fibroblast proliferation. The method involves using a compound that reduces the level of tyrosine phosphatase activity effected by the protein EYA1A in the parenchymal organ, a nucleic acid ligase IV inhibitor, or an antisense oligonucleotide against the p53-binding protein 1 (53BP1).

  本发明提供了一种预防、治疗或延缓涉及成纤维细胞异常增殖的疾病进展的方法。该方法包括使用能降低实质器官中由蛋白 EYA1A 影响的酪氨酸磷酸酶活性水平的化合物、核酸连接酶 IV 抑制剂或针对 p53 结合蛋白 1（53BP1）的反义寡核苷酸。
• TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION
  申请人：Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin

  公开号：US20210137963A1

  公开（公告）日：2021-05-13

  Provided is a method of preventing, treating or delaying progression of a disease involving aberrant fibroblast proliferation. The method involves using a compound that reduces the level of tyrosine phosphatase activity effected by the protein EYA1A in the parenchymal organ, a nucleic acid ligase IV inhibitor, or an antisense oligonucleotide against the p53-binding protein 1 (53BP1).